Scarica l'app Stockscreener
360.46
2.61%
-9.503
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$369.96
Aprire:
$369.95
Volume 24 ore:
435.67K
Relative Volume:
0.33
Capitalizzazione di mercato:
$47.60B
Reddito:
$3.21B
Utile/perdita netta:
$43.57M
Rapporto P/E:
1,498.78
EPS:
0.2405
Flusso di cassa netto:
$221.36M
1 W Prestazione:
-14.72%
1M Prestazione:
-9.37%
6M Prestazione:
+14.11%
1 anno Prestazione:
+49.80%
Intervallo 1D:
$360.18
$371.71
Intervallo di 1 settimana:
$353.52
$425.19
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
360.32 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.32 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.46 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
802.44 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
346.62 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal - Yahoo Finance UK
Market Review: What dividend safety score for Alnylam Pharmaceuticals Inc stockIndex Update & Reliable Intraday Trade Alerts - moha.gov.vn
H.C. Wainwright reiterates Buy rating on Alnylam stock with $570 price target - Investing.com UK
Alnylam Pharmaceuticals CEO on Development Goals, Profitability - marketscreener.com
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY - TechStock²
Lobbying Update: $70,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance - BioWorld MedTech
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short - TechStock²
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. - Yahoo Finance
JPM preannouncements take their toll as Alnylam slides, Tempus, Day One pop - MSN
JPM Kicks Off With Alnylam In the Red; But Others Surge - Investor's Business Daily
What's Going On With Alnylam Pharma Stock Monday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam (ALNY) Projects Strong Revenue Growth for 2026 Amidst TT - GuruFocus
B of A Securities Lowers Price Target for ALNY While Maintaining Buy Rating | ALNY Stock News - GuruFocus
Needham raises Alnylam Pharmaceuticals stock price target on strong 2026 guidance - Investing.com UK
Alnylam Pharmaceuticals (ALNY) Receives Rating Reaffirmation and Price Target Increase | ALNY Stock News - GuruFocus
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - Yahoo Finance
Alnylam stock price target lowered to $529 by BofA on Q4 revenue miss - Investing.com UK
Raymond James reiterates Outperform rating on Alnylam stock at $472 target - Investing.com UK
Alnylam Pharmaceuticals stock rises as Goldman Sachs reiterates Buy rating By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Unveiling a 22.96% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Alnylam Unveils 'Alnylam 2030' Strategy To Drive Growth And Innovation - Nasdaq
Los Angeles Daily NewsAlnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact - FinancialContent
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact - FinancialContent
Will Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)? - simplywall.st
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 19% ROE Better Than Average? - Yahoo Finance
Alnylam raises 2025 revenue guidance to $3.05B amid robust AMVUTTRA ATTR-CM launch momentum - MSN
ALNYLAM PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $ALNY Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterJuly 2025 Sentiment & Safe Entry Trade Signal Reports - ulpravda.ru
Is It Too Late To Consider Alnylam Pharmaceuticals (ALNY) After Its 67% One Year Surge - simplywall.st
Trading the Move, Not the Narrative: (ALNY) Edition - Stock Traders Daily
Gene Therapy Market to Reach US$ 35.91 Billion by 2033 | CAGR 23.1% - openPR.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock testing key supportEarnings Risk Summary & Capital Efficient Trade Techniques - ulpravda.ru
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As It Previews New Five Year Plan And Revenue Outlook - simplywall.st
How buybacks impact Alnylam Pharmaceuticals Inc. stock valueJuly 2025 Chart Watch & Fast Entry and Exit Trade Plans - ulpravda.ru
Is Alnylam Pharmaceuticals Inc. stock safe for conservative investorsWeekly Trend Summary & Reliable Volume Spike Alerts - ulpravda.ru
Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Seems To Use Debt Quite Sensibly - Yahoo Finance
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical - GlobeNewswire Inc.
Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favorite2026 world cup usa national team group stage young talents build up play winner prediction statistical analysis - ulpravda.ru
Bernstein lowers Alnylam stock price target to $491 on slowing Amvuttra sales - Investing.com UK
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation - Chartmill
Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion - openPR.com
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Generali Asset Management SPA SGR Has $1.48 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Western Financial Corp CA Invests $1.24 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500 - FinancialContent
Aug Closing: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Action & Risk Controlled Swing Alerts - moha.gov.vn
U.S. Transthyretin Amyloidosis Treatment Market Insights - openPR.com
Cardiovascular Biologics Market to Reach USD 4.23 Billion - openPR.com
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Nov 26 '25 |
Option Exercise |
106.40 |
4,697 |
499,756 |
70,106 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Option Exercise |
119.13 |
8,161 |
972,220 |
33,392 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Sale |
452.18 |
12,128 |
5,483,990 |
21,264 |
1.11%
1.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):